An IgM Lupus Anticoagulant that Neutralizes the Enhancing Effect of Phospholipid on Purified Endothelial Thrombomodulin Activity-A Mechanism for Thrombosis

J-M Freyssinet; Marie-Louise Wiesel; Josiane Gauchy; B Boneu; J-P Cazenave

doi:10.1055/s-0038-1661553

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 55(03): 309-313
DOI: 10.1055/s-0038-1661553

Original Article

Schattauer GmbH Stuttgart

An IgM Lupus Anticoagulant that Neutralizes the Enhancing Effect of Phospholipid on Purified Endothelial Thrombomodulin Activity-A Mechanism for Thrombosis

Authors

J-M Freyssinet

¹The Laboratoire de Biologie et de Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France
Marie-Louise Wiesel

¹The Laboratoire de Biologie et de Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France
Josiane Gauchy

¹The Laboratoire de Biologie et de Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France
B Boneu

²The Laboratoire d’Hemostase, Centre Regional de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
J-P Cazenave

¹The Laboratoire de Biologie et de Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France

Abstract

PDF Download

Summary

An anticoagulant activity was isolated from the plasma of a patient with a strong lupus-like anticoagulant using gel filtration by high performance liquid chromatography. IgM were detected in this anticoagulant fraction which exhibited specificity towards 50% phosphatidylcholine - 50% phosphatidylserine vesicles and cardiolipin. These phospholipids were able to produce an apparent 3-fold enhancement of purified human protein C activation by human a-thrombin in the presence of purified human placenta thrombomodulin. In the absence of phospholipid, the anticoagulant fraction had no effect on thrombomodulin activity. The anticoagulant fraction could neutralize the enhancement of thrombomodulin activity by phospholipid in a dose-dependent manner. This study suggests that the neutralization of phospholipid might result in a reduced activation of protein C which could be responsible for the occurrence of thrombotic complications in a proportion of patients with lupus anticoagulants.

Keywords

Lupus anticoagulant - Thrombosis - Phospholipid - Thrombomodulin - Protein C

PDF (516 kb)

References

References
1 Shapiro SS, Thiagarajan P. Lupus anticoagulants. In: Progress in Hemostasis and Thrombosis. Spaet TH. (Ed) Grune and Stratton; Orlando: 1982. 6 263-285
2 Bowie EJ W, Thompson Jr JH, Cascuzzi PA, Owen Jr GA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
3 Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ W. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Amer J Hematol 1985; 19: 265-275
4 Lechner K, Pabinger-Fashing I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-262
5 Cazenave JP, Klein-Soyer C, Beretz A. The vascular endothelium. An important site of blood-tissue exchanges. Inter Angio 1984; 3: 27-32
6 Feinstein DI. Lupus anticoagulant, thrombosis, and fetal loss. N Engl J Med 1985; 313: 1348-1350
7 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: Detection of immunoglobulin interfering with prostacyclin production. Lancet 1981; 01: 244-246
8 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. Blood 1983; 62 (05) (Suppl. 01) 299 Abstr
9 Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem 1980; 49: 765-811
10 Zwall RFA. Membrane and lipid involvement in blood coagulation. Biochim Biophys Acta 1978; 515: 163-205
11 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin MX coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
12 Harris EN, Gharavi EA, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GV R. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214
13 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-2252
14 Stenflo J. Structure and function of protein C. Semin Thromb Hemostasis 1984; 10: 109-121
15 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-11131
16 Griffin JH. Clinical studies of protein C. Semin Thromb Hemostasis 1984; 10: 162-166
17 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
18 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300
19 Freyssinet JM, Gauchy J, Spaethe R, Fritsche R, Cazenave JP. Effects of concanavalin A and phospholipases A₂and C on thrombomodulin and thromboplastin activities extracted from human placenta. Thromb Haemostas 1985; 54: 83 Abstr
20 Freyssinet JM, Brami B, Gauchy J, Cazenave JP. Coextraction of thrombomodulin and tissue factor from human placenta: Effects of concanavalin A and phospholipid environment on activity. Thromb Haemostas 1986; 55: 112-118
21 Esmon CT, Esmon NL, Johnson AE, DeBault L, Galvin J. Cellular control of protein C activation. Thromb Haemostas 1985; 54: 234 Abstr
22 Caen J, Larrieu MJ, Samama M. L’Hémostase. Expansion Scientifi-que, Paris 1975
23 Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-864
24 Freyssinet JM, Grunebaum L, Wiesel ML, Cazenave JP, Fritsche R, Greber S, Lampart A, Spaethe R. Production of an antibody against protein C and its use to detect patients with congenital protein C deficiency associated with thrombosis. In: Protein C. Biochemical and Medical Aspects Witt I. (Ed) Walter de Gruyter; Berlin: 1985: 107-116
25 Freyssinet JM, Thevenon D, Souque A, Suscillon M. Reversible inhibition of the in vitro coagulation of human plasma by lectins. Thomb Haemostas 1982; 48: 120-124
26 Owen WG, Jackson CM. Activation of prothrombin with Oxyuranus scutellatus scutellatus (taipan snake) venom. Thromb Res 1973; 3: 705-714
27 Salem HH, Maruyama I, Ishii H, Majerus PW. Isolation and characterization of thrombomodulin from human placenta. J Biol Chem 1984; 259: 12246-12251
28 Johnstone A, Thorpe R. Immunochemistry in Practice. Blackwell Scientific Publications, Oxford 1982
29 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases anti-activator activity. Proc Natl Acad Sci USA 1985; 82: 1121-1125
30 Van Hinsberg VW M, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
31 Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979; 94: 312-323
32 Soulier JP, Boffa MC. Avortements a repetition, thromboses et anticoagulant circulant anti-thromboplastine: trois observations. Nouv Presse Med 1980; 9: 859-864